SureTrader
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Foxwoods Man, drkazmd65
Search This Board:
Last Post: 8/30/2016 1:23:46 PM - Followers: 165 - Board type: Free - Posts Today: 0

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4

Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
     
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  

    Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

     
    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

     
    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

     

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM
Current Price
Volume:
Bid Ask Day's Range
SureTrader
CVM News: CEL-SCI Announces the Closing of Its $5 Million Registered Direct Offering 08/29/2016 09:00:00 AM
CVM News: Current Report Filing (8-k) 08/24/2016 11:54:55 AM
CVM News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 08/24/2016 06:03:40 AM
CVM News: CEL-SCI Announces $5 Million Registered Direct Offering 08/23/2016 09:00:00 AM
CVM News: CEL-SCI Corporation Reports Third Quarter Fiscal Year 2016 Financial Results 08/10/2016 08:00:00 AM
PostSubject
#7838  Sticky Note $CVM recent news/filings mick 01/18/16 02:09:58 PM
#7359  Sticky Note News! Ergomed Increases Its Co-Development Contribution up to $12,000,000 trickledownfacists 10/05/15 08:40:16 AM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#8519   Nah!!! They are awesome in caring for shareholders. ducruacuteo11 08/30/16 01:23:46 PM
#8518   I'm just going off of what the research trickledownfacists 08/29/16 09:09:39 PM
#8516   http://www.barchart.com/interactive_charts/stocks/CVM mick 08/29/16 05:57:50 PM
#8515   Hmmm...it does not say the location was terminated Foxwoods Man 08/29/16 04:42:57 PM
#8514   As of 5 minutes ago I have received trickledownfacists 08/29/16 03:45:29 PM
#8513   Agreed, management transparency is poor. trickledownfacists 08/29/16 03:03:12 PM
#8512   IMO management has no regard to shareholders or tprosuper 08/29/16 02:33:47 PM
#8511   I hope you are correct but...this does have Foxwoods Man 08/29/16 02:15:49 PM
#8510   I disagree, with the private equity placement, and trickledownfacists 08/29/16 02:04:32 PM
#8509   Aren't they expect to win? Or do Foxwoods Man 08/29/16 02:00:41 PM
#8508   Yup, hoping for the best trickledownfacists 08/29/16 01:46:21 PM
#8507   Well, this is way more conservative than Geerts' speeches. Kami_ss 08/29/16 01:35:57 PM
#8506   That is irrelevant to my point. Regardless of Kami_ss 08/29/16 01:30:25 PM
#8505   I think it's the "better safe than sorry" trickledownfacists 08/29/16 01:23:29 PM
#8504   Well, that was my first point... didn't they Kami_ss 08/29/16 01:18:11 PM
#8503   The offering funds are not to cover expenses sinity 08/29/16 12:36:44 PM
#8502   Yes, but all that is based on a trickledownfacists 08/29/16 12:30:36 PM
#8501   Sure, I get it. But if they had Kami_ss 08/29/16 12:10:29 PM
#8500   It's not very good business practice to run trickledownfacists 08/29/16 11:49:08 AM
#8499   So they could have waited until early Sept... Kami_ss 08/29/16 11:34:38 AM
#8498   They would have run out of money at trickledownfacists 08/29/16 11:14:10 AM
#8497   My main concern with the recent offering is Kami_ss 08/29/16 11:02:33 AM
#8493   Plus who wants to go forward with a trickledownfacists 08/26/16 06:14:23 PM
#8492   Continued.... Advent paid $1.9 billion cash for trickledownfacists 08/26/16 06:01:35 PM
#8491   Correct. Advent paid $1.9 billion trickledownfacists 08/26/16 05:59:38 PM
#8490   Was doing a bit of background research & drkazmd65 08/26/16 04:36:12 PM
#8489   I swapped my warrants for shares today also. ducruacuteo11 08/25/16 03:43:17 PM
#8488   You can get a tax loss by selling Turney 08/25/16 01:23:06 PM
#8487   my logic (other than the expiration issue)..flawed as Foxwoods Man 08/25/16 01:19:44 PM
#8486   FM, what's your hurry? We have until ducruacuteo11 08/25/16 12:53:30 PM
#8485   Well I just put 9000 of them up Foxwoods Man 08/25/16 12:00:31 PM
#8484   interesting action timothy6 08/25/16 11:13:15 AM
#8483   They only needed 15 patients...two years and couldn't Foxwoods Man 08/25/16 06:49:02 AM
#8482   I called the university of San Fran. trickledownfacists 08/24/16 11:57:32 PM
#8481   That may be but people with a lot Turney 08/24/16 09:01:01 PM
#8480   I always "assumed" that they had more info Foxwoods Man 08/24/16 04:38:36 PM
#8479   Don't you think that, for someone that is ducruacuteo11 08/24/16 04:36:27 PM
#8478   In order for the big buyers to make Foxwoods Man 08/24/16 03:19:59 PM
#8477   So they can sell them out in the ducruacuteo11 08/24/16 03:02:01 PM
#8476   Maybe someone can expand but I believe the Foxwoods Man 08/24/16 02:52:10 PM
#8475   Does anyone know if the investors that purchase ducruacuteo11 08/24/16 02:48:22 PM
#8474   Thanks for ruining my last hope on multikine. ducruacuteo11 08/24/16 02:45:52 PM
#8473   O wow really wow u knew and everyone pijoe 08/24/16 02:07:55 PM
#8472   The BIG issue here is that everyone ASSUMES Foxwoods Man 08/24/16 02:02:27 PM
#8471   Well that makes sense...2 1/2 years and they Foxwoods Man 08/24/16 02:01:01 PM
#8470   Not Good,... I wonder what (specifically) the issue(s) drkazmd65 08/24/16 01:00:29 PM
#8469   You don't think you predicted anything we all Turney 08/23/16 05:37:08 PM
#8468   Funny I said this was gonna happen yesterday pijoe 08/23/16 05:27:17 PM
#8467   More dilution and the sky isn't falling. DON'T Turney 08/23/16 01:22:39 PM
#8466   FM, It's O.K. Geert is only making $500K ducruacuteo11 08/23/16 01:15:27 PM
PostSubject